Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Bronx, NY
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
New Bern, NC
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
New Bern, NC
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Englewood, OH
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Englewood, OH
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Gallipolis, OH
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Gallipolis, OH
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
West Reading, PA
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
West Reading, PA
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Columbia, SC
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Greenville, SC
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Myrtle Beach, SC
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Austin, TX
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
McAllen, TX
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Sandy, UT
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Sandy, UT
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Norfolk, VA
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated:  3/1/2016
mi
from
Antwerpen,
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Status: Enrolling
Updated: 3/1/2016
mi
from
Antwerpen,
Click here to add this to my saved trials
PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
Phase I/II Study of PCI-24781 in Combination With Doxorubicin for Treatment of Advanced Sarcomas Following Failure or Prior Anthracycline Therapy
Status: Enrolling
Updated:  3/1/2016
Massachusetts General Hospital
mi
from
Boston, MA
PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
Phase I/II Study of PCI-24781 in Combination With Doxorubicin for Treatment of Advanced Sarcomas Following Failure or Prior Anthracycline Therapy
Status: Enrolling
Updated: 3/1/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
Phase I/II Study of PCI-24781 in Combination With Doxorubicin for Treatment of Advanced Sarcomas Following Failure or Prior Anthracycline Therapy
Status: Enrolling
Updated:  3/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
Phase I/II Study of PCI-24781 in Combination With Doxorubicin for Treatment of Advanced Sarcomas Following Failure or Prior Anthracycline Therapy
Status: Enrolling
Updated: 3/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer
Status: Enrolling
Updated:  3/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer
Status: Enrolling
Updated: 3/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Curcumin Biomarker Trial in Head and Neck Cancer
An Exploratory Biomarker Trial of the Food Substances Curcumin C3 Complex® in Subjects With Newly Diagnosed Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/1/2016
LSUHSC-Shreveport and Feist-Weiller Cancer Center
mi
from
Shreveport, LA
Curcumin Biomarker Trial in Head and Neck Cancer
An Exploratory Biomarker Trial of the Food Substances Curcumin C3 Complex® in Subjects With Newly Diagnosed Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/1/2016
LSUHSC-Shreveport and Feist-Weiller Cancer Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  3/1/2016
Barbara Ann Karmanos Cancer Center
mi
from
Detroit, MI
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 3/1/2016
Barbara Ann Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  3/1/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 3/1/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  3/1/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 3/1/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  3/1/2016
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 3/1/2016
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  3/1/2016
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 3/1/2016
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  3/1/2016
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 3/1/2016
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
Status: Enrolling
Updated:  3/1/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
Status: Enrolling
Updated: 3/1/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy
A Prospective Trial to Evaluate Whether Variations in Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy
Status: Enrolling
Updated:  3/1/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy
A Prospective Trial to Evaluate Whether Variations in Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy
Status: Enrolling
Updated: 3/1/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  3/1/2016
Missouri Valley Cancer Consortium
mi
from
Omaha, NE
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 3/1/2016
Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  3/1/2016
The Cleveland Clinic, Taussig Cancer Institute
mi
from
Cleveland, OH
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 3/1/2016
The Cleveland Clinic, Taussig Cancer Institute
mi
from
Cleveland, OH
Click here to add this to my saved trials
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  3/1/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 3/1/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
CASE 10813: A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Carcinoma
Status: Enrolling
Updated:  3/1/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
CASE 10813: A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Carcinoma
Status: Enrolling
Updated: 3/1/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
CASE 10813: A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Carcinoma
Status: Enrolling
Updated:  3/1/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
CASE 10813: A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Carcinoma
Status: Enrolling
Updated: 3/1/2016
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer
CT Metrology: Quantitative Imaging Metrics With Advanced Visualization Tools for Cancer Imaging
Status: Enrolling
Updated:  3/1/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer
CT Metrology: Quantitative Imaging Metrics With Advanced Visualization Tools for Cancer Imaging
Status: Enrolling
Updated: 3/1/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer
A Phase III Intensity Modulated Radiotherapy Dose Escalation Trial for Prostate Cancer Using Hypofractionation
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer
A Phase III Intensity Modulated Radiotherapy Dose Escalation Trial for Prostate Cancer Using Hypofractionation
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer
Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy (IMRT) With Incorporated Boost in Early Stage Breast Cancer
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer
Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy (IMRT) With Incorporated Boost in Early Stage Breast Cancer
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
PTK787/ZK222584 and RAD001 for Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  3/1/2016
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
PTK787/ZK222584 and RAD001 for Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 3/1/2016
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Howard University Cancer Center
mi
from
Washington,
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Howard University Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Medical College of Georgia Cancer Center
mi
from
Augusta, GA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Medical College of Georgia Cancer Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County
mi
from
Mount Holly, NJ
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County
mi
from
Mount Holly, NJ
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Hematology Oncology Associates of Central New York, PC - Northeast Center
mi
from
East Syracuse, NY
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Hematology Oncology Associates of Central New York, PC - Northeast Center
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
CCOP - Main Line Health
mi
from
Wynnewood, PA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
CCOP - Main Line Health
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Nashville General Hospital at Meharry
mi
from
Nashville, TN
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Nashville General Hospital at Meharry
mi
from
Nashville, TN
Click here to add this to my saved trials
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
Efficacy and Feasibility of a Psychosocial Intervention Within the CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
Efficacy and Feasibility of a Psychosocial Intervention Within the CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials